Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue was supported by semiconductor-related demand, price management for industrial gases and other products, revisions to LP gas selling prices and higher market prices, new medical equipment orders, the consolidation of the dental materials and supplies mail-order business, and expanded sales of private-label products and various merchandise. Operating profit declined because the company recognized ¥9.693 billion in outsourcing costs paid to external specialists and others in connection with measures to address inappropriate accounting and prevent recurrence, despite these revenue growth and improvement factors.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥283,309 million (YoY +18.2%) |
| Operating profit | ¥13,770 million (YoY -13.7%) |
| Ordinary income | ¥12,247 million (YoY -21.7%) |
| Profit attributable to owners of the parent | ¥6,075 million (YoY -35.1%) |
| Net income per share | ¥26.50 |
| Equity ratio | End of the current fiscal period 32.8 / End of previous period 32.9 |
| Total assets | ¥1,244,095 million |
| Net assets | ¥429,038 million |
| Cash flows from operating activities | ¥7,209 million |
| Cash flows from investing activities | ¥-13,362 million |
| Cash flows from financing activities | ¥7,754 million |
| Cash and cash equivalents at end of period | ¥88,342 million |
| Full-year earnings forecast | Net Sales ¥1,140,000 million (YoY +6.9%) / Operating profit ¥48,000 million / Ordinary income ¥44,000 million / Net income ¥28,000 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 75 Yen → Undecided |
| Segment revenue | Digital & Industry ¥82,222 million (YoY +106.3%), Energy Solutions ¥23,678 million (YoY +111.4%), Health & Safety ¥89,857 million (YoY +173.7%), Agri & Foods ¥34,655 million (YoY +91.2%), Other Businesses ¥52,896 million (YoY +102.9%) |
| Segment profit | Digital & Industry ¥8,055 million (YoY +104.2%), Energy Solutions ¥2,577 million (YoY +129.8%), Health & Safety ¥7,152 million (YoY +291.9%), Agri & Foods ¥1,952 million (YoY +101.6%), Other Businesses ¥3,235 million (YoY +162.8%) |
| Depreciation and amortization | ¥13,843 million |
| Impairment loss | ¥567 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Yes |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not applicable / Excluded Number of companies 0 / Company name Not applicable |
| Material subsequent events | The company drew a total of ¥60 billion between 29 July and 30 October 2026 under a syndicated commitment line agreement. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 229,755,057 |
| Treasury Shares at Period-End | 530,111 |
| Factors Behind Changes in Business Performance | Revenue was supported by semiconductor-related demand, price management for industrial gases and other products, revisions to LP gas selling prices and higher market prices, new medical equipment orders, the consolidation of the dental materials and supplies mail-order business, and expanded sales of private-label products and various merchandise. Operating profit declined because the company recognized ¥9.693 billion in outsourcing costs paid to external specialists and others in connection with measures to address inappropriate accounting and prevent recurrence, despite these revenue growth and improvement factors. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company recognized outsourcing costs paid to external specialists and others in connection with implementing measures to prevent recurrence in response to inappropriate accounting, ongoing accounting self-inspections, and measures aimed at lifting the designation as a security under special monitoring. Revenue was supported by semiconductor-related demand, price management, LP gas market conditions, and the effects of newly consolidated businesses, among other factors.